65645-57-0

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 2-(3-AMINOPYRIDIN-4-YL)ACETATE is utilized as a building block in the synthesis of various pharmaceuticals. Its presence in the molecular structure of target compounds can contribute to their therapeutic effects, making it a valuable component in drug discovery and development.
Used in Organic Synthesis:
In the realm of organic chemistry, ETHYL 2-(3-AMINOPYRIDIN-4-YL)ACETATE serves as a key intermediate for the preparation of a wide array of biologically active molecules. Its reactivity and structural features facilitate the creation of complex organic compounds with potential applications in various fields.
Used as a Precursor in Chemical Research:
ETHYL 2-(3-AMINOPYRIDIN-4-YL)ACETATE is also employed as a precursor for the synthesis of pyridine-based ligands and catalysts. Its role in the development of these specialized chemical agents is crucial for advancing research in catalysis and coordination chemistry, which can have broad implications in material science and environmental chemistry.
Used in Medicinal Chemistry:
ETHYL 2-(3-AMINOPYRIDIN-4-YL)ACETATE's properties make it suitable for use in medicinal chemistry, where it can be incorporated into drug candidates to enhance their pharmacological profiles. Its ability to form various chemical bonds and its compatibility with different molecular frameworks make it a promising candidate for the design of new therapeutic agents.

Upstream product

• 626-64-2 pyridin-4-ol 
• 5435-54-1 4-hydroxy-3-nitropyridine 
• 13091-23-1 4-chloro-3-nitropyridine 
• 65645-51-4 ethyl 2-(3-nitropyridin-4-yl)-3-oxobutanoate 
• 932702-14-2 1-(tert-butyl) 3-ethyl 2-(3-nitropyridin-4-yl)malonate 
• 65645-52-5 ethyl 2-(3-nitro-pyridin-4-yl)acetate 

Downstream Products

• 932702-13-1 1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 
• 1338219-56-9 ethyl {3-[(tert-butoxycarbonyl)amino]pyridin-4-yl}acetate 
• 486422-87-1 tert-butyl [4-(2-hydroxyethyl)pyridin-3-yl]carbamate 

Relevant academic research and scientific papers

RESPIRATORY SYNCYTIAL VIRUS INHIBITORS

Compounds of Formula (I): wherein W is NR1A or CR1BR1B; Z is N or CH, R1A is C1-C3alkyl, C1-C3haloalkyl, C3-C4cycloalkyl or phenyl wherein cycloalkyl or phenyl is optionally mono-, di- or tri-substituted with substituents each independently selected from C1- C3alkyl, halo, amino and C1-C3alkoxy; the two R1B together with the carbon atom to which they are attached combine and form C3- C6cycloalkyl or heterocyclyl, wherein the cycloalkyl is substituent with C(=O)OR1C, NHC(=O)OR1C or NHS(=O)2 R1C, and the heterocyclyl is substituent with C(=O)R1C, C(=O)OR1C, S(=O)2 R1C, C(=O)NH2 or C(=O)NR1CR1C'; q, n, R1C, R2 and R3 are as defined herein, their use as inhibitors of RSV and related aspects.

RESPIRATORY SYNCYTIAL VIRUS INHIBITORS

Compounds of Formula (I): wherein W is NR1A or CR1BR1B; Z is N or CH; R1A is C1-C3alkyl, C1-C3haloalkyl C3-C4cycloalkyl or phenyl wherein cycloalkyl or phenyl is optionally mono-, di- or tri-substituted with substituents each independently selected from C1- C3alkyl, halo, amino and C1-C3alkoxy; the two R1B together with the carbon atom to which they are attached combine and form C3-C6cycloalkyl or heterocyclyl, wherein the cycloalkyl is substituent with C(=O)OR1C, NHC(=O)OR1C or NHS(=O)2R1C, and the heterocyclyl is substituent with C(=O)R1C, C(=O)OR1C, S(=O)2 R1C, C(=O)NH2 or C(=O)NR1CR1C'; n is 0, 1 or 2; n, q, R1C, R1C', R2 and R3 are as defined herein, their use as inhibitors of RSV and related aspects.

RESPIRATORY SYNCYTIAL VIRUS INHIBITORS

Compounds of Formula (I): (Formula I), wherein Z1 is NR1A, CHR1A or CR1BR1B; one of Z2 and Z3 is CH or CR1A', the other is N, CH or CR1A'; n is 0, 1 or 2; q is 0, 1 or 2; R1A, R1A', R1B, R2 and R3 are as defined herein, their use as inhibitors of RSV and related aspects.

SPIRO UREA COMPOUNDS AS RSV ANTIVIRAL COMPOUNDS

The invention concerns novel substituted spiro urea azetidinyl or piperidinyl compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention furth

RSV ANTIVIRAL COMPOUNDS

Inhibitors of RSV replication of formula RI including stereochemically isomeric forms, and salts or solvates thereof, wherein R22, W, Q, V, Z p,s,and Het have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other RSV inhibitors, in RSV therapy.

Preparation of azaindolines and benzoyl substituted azaindolines: Precursors of triazabenzo[cd]azulen-9-one PDE4 inhibitors

The syntheses of various substituted azaindolines are described. Azaindolines were identified as potential key intermediates towards new PDE4 inhibitors.

Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof

The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (e.g., indazoles and benzothiazoles), which act as ligands for the α7 nACh receptor subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.